Travere Therapeutics (TVTX) Non-Current Deffered Revenue (2021 - 2024)
Travere Therapeutics (TVTX) posted Non-Current Deffered Revenue of $888000.0 for Q1 2024, down 51.61% on a QoQ basis from $1.8 million in Q4 2023, and down 89.88% year-over-year from $8.8 million in Q2 2023.
Travere Therapeutics (TVTX) Non-Current Deffered Revenue (2021 - 2024) Analysis & Trends
Travere Therapeutics' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $888000.0 for Q1 2024.
- Quarterly Non-Current Deffered Revenue fell 89.88% year-over-year to $888000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $888000.0 (down 89.88% YoY) and the FY2023 annual result came in at $1.8 million, down 83.21% from the prior year.
- Non-Current Deffered Revenue was $888000.0 for Q1 2024 at Travere Therapeutics, down from $1.8 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $24.1 million in Q3 2021 and bottomed at $888000.0 in Q1 2024.
- A 4-year average of $11.6 million and a median of $10.9 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue sank 46.36% — and 2024, when it slumped 89.88%.
- Travere Therapeutics' Non-Current Deffered Revenue stood at $20.4 million in 2021, then plunged by 46.36% to $10.9 million in 2022, then plunged by 83.21% to $1.8 million in 2023, then slumped by 51.61% to $888000.0 in 2024.
- Business Quant data shows TVTX's Non-Current Deffered Revenue at $888000.0 in Q1 2024, $1.8 million in Q4 2023, and $4.6 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 888,000.00 |
| Dec 31, 2023 | 1.84 Mn |
| Sep 30, 2023 | 4.57 Mn |
| Jun 30, 2023 | 6.79 Mn |
| Mar 31, 2023 | 8.78 Mn |
| Dec 31, 2022 | 10.93 Mn |
| Sep 30, 2022 | 12.92 Mn |
| Jun 30, 2022 | 16.24 Mn |
| Mar 31, 2022 | 19.67 Mn |
| Dec 31, 2021 | 20.38 Mn |
| Sep 30, 2021 | 24.08 Mn |